Company / Operating Income
Adaptimmune Therapeutics PLC Operating Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$68.8M
FY2024
5-year range
-$164.0M / -$68.8M
FY2020-FY2024
Trend
+50.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 9 years, ranging from -$164M in FY2022 to -$69M in FY2024.
Based on SEC 10-K filings.
-$69M in FY2024.
Improved from -$164M to -$69M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating income increased 50.8% year-over-year.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$68.8M | +50.8% |
| FY2023 | -$139.7M | +14.8% |
| FY2022 | -$164.0M | -1.1% |
| FY2021 | -$162.2M | -21.6% |
| FY2020 | -$133.4M | +4.6% |
| FY2019 | -$139.8M | -69.7% |
| FY2018 | -$82.4M | -2.1% |
| FY2017 | -$80.7M | -10.8% |
| FY2016 | -$72.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026